Fresenius Medical Care

Fresenius Medical Care AG & Co. KgaA provides products and services for individuals with renal diseases. The firm develops and manufactures health care products, which includes dialysis and non-dialysis products. It operates through the following segments: North America Segment, EMEA Segment, Asia-Pacific Segment and Latin America Segment. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius SE & Co. KGaA's (FSNUF) CEO Stephan Sturm on Q3 2019 Results - Earnings Call Transcript

Fresenius Medical Care's (FMS) CEO Rice Powell on Q3 2019 Results - Earnings Call Transcript

Fresenius has problems in its Fresenius Medical Care segment and the US Fresenius Kabi market, and the Helios hospitals in Germany are also stagnating.

Fresenius: Valuation Doesn't Reflect The Growth Potential

Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

Fresenius Medical Launches 4008A Dialysis Machine in China

Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now from multiple angles.

Is Fresenius Medical (FMS) a Good Value Investor Pick Now?

Fresenius SE & Co. KGaA (FSNUF) CEO Stephan Sturm on Q2 2019 Results - Earnings Call Transcript

Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.

Fresenius Medical (FMS) Q2 Earnings Miss Estimates, Down Y/Y

Fresenius Medical Care AG & Co. KGaA (FMS) CEO Rice Powell on Q2 2019 Results - Earnings Call Transcript

Discover

PACCAR

Screening for securities that are more than doubling 20-year high-quality corporate bonds' earnings yields raises the possibility of gaining impressive margins.

3-Large Cap Stocks Offer High Earnings Yields

CVS Health

DaVita

CVS Health began a trial of a home dialysis system that could cut into a market controlled by Fresenius Medical and DaVita. But all three stocks fell.

CVS Health Tests Home Dialysis System; DaVita, Fresenius Hit

Fresenius appears better prepared than DaVita for market transition from outpatient to home dialysis caused by the Trump kidney initiative

Why Fresenius Is the Initial Winner From Trump’s Kidney Disease Overhaul

Amgen

Baxter

Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.

Trump's Order on Kidney Care Lifts These Dialysis Stocks

CareDx

President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.

Trump's Kidney Disease Executive Order May Boost This Health Stock, Tank Others

The executive order would create new payment models to encourage more kidney transplants and give patients incentives to seek dialysis treatment at home instead of at more expensive treatment centers, HHS Secretary Alex Azar says.

Trump to sign executive order overhauling kidney transplant, dialysis market

Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.

Fresenius Set for Global Expansion of Research Activities

Fresenius Medical Care AG & Co. KGaA (FMS) CEO Robert Powell on Q1 2019 Results - Earnings Call Transcript

Fresenius is a very diversified company with dialysis products, hospital supplies, hospital operation as well as projects and services for hospitals.

Fresenius SE: Not Exceptional, But A Very Good Investment

The Securities and Exchange Commission on Friday announced that Fresenius Medical Care AG & Co KGaA, a German medical device company, has agreed to pay over $231 million to settle charges brought by the Department of Justice and SEC.

Fresenius Medical Care to pay $231 million to settle bribery charges

Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

Fresenius Medical's New Hemodialysis Software Gets FDA Nod

News for Fresenius Medical Care Stock (FMS)